Click here for YNHH home page.


Sign up for HealthLINK.

Can we help?

Follow up on this month's He@lthLINK

 


Phone Numbers

Directory assistance
(203) 688-4242

Patient information
(203) 688-4177

Adult emergency
(203) 688-2222

Children's emergency
(203) 688-3333

Admitting
(203) 688-2221

Children's admitting
(203) 688-3331

Psychiatric admitting
(203) 688-9907



Mailing address:
Yale-New Haven
Children's Hospital
20 York Street
New Haven, CT
06510-3202





Yale-New Haven Hospital, New Haven, Connecticut, USA HealthLINK: Pediatrics
December 22, 2000

News this month
New pertussis vaccine proven safer

A newer vaccine for whooping cough (pertussis) is proving to be safer than the older vaccine, according to a recent study that examined complications following vaccination.

The pertussis vaccine is commonly given to infants in combination with diphtheria and tetanus vaccines–a combination called the DTP vaccine. If the Haemophilus influenzae type b vaccine is included, the vaccine is called DTPH. In 1996, the U.S. Food and Drug Administration approved the first "acellular" pertussis vaccine for use in infants. This new vaccine was developed in response to concerns expressed during the 1970s and 1980s about the safety of the less purified whole-cell pertussis vaccine.

Publicity about a small number of serious pertussis vaccine reactions in children led to an anti-vaccination movement which doctors consider more dangerous than the vaccine itself.

Several national studies released in the early 1990s linked the whole-cell vaccine with causing a small number of serious nervous disorders and deaths in children. Publicity about these reactions in children led to an anti-vaccination movement in several countries, a trend which doctors cite as being ultimately more dangerous than the vaccine itself.

Drop in serious side effects
Acellular pertussis was first licensed in July 1996 after clinical trials showed it was as or more effective than the whole-cell vaccine in infants. Millions of doses of DTaP vaccine have now been given. The current study in the October issue of Pediatrics showed that the incidence of serious side effects declined dramatically from 1995 to mid 1998. During this time, there were 285 reports involving death, 971 nonfatal serious reports and 4,514 less serious reports after immunization with any pertussis-containing vaccine. Highlights of the results show that:

  • During the study, the annual number of deaths dropped from 85 in 1995 to 41 in the first half of 1998.
  • Serious complications declined from 334 in 1995 to 93 in the first half of 1998. Serious complications were defined as life-threatening, requiring hospitalization or causing permanent disability.
  • Less serious complications, such as fever and crying, declined from 1,652 in 1995 to 357 in the first half of 1998.
Using the DTaP vaccine, the incidence of serious side effects declined dramatically.

Types of side effects seen
Fever was the most commonly reported side effect for both DTP and DTPH (43.9% and 38.8%), followed by agitation (31.4% for DTP and 30.5% for DTPH). Using the new DTaP vaccine, agitation was reported as the most common side effect (25.7%), with fever dropping to second (25%) place. The acellular version also caused less irritation at the injection site.

Limitations on data
Complications in infants less than one year old, occurring in the U.S., were reported to the federal Vaccine Adverse Event Reporting System (VAERS), which was established in 1990 to help track the safety of new vaccines. No foreign data was included. Because of the way the reporting process works, not all complications may be directly related to the vaccine. Underreporting can also occur. Despite the limitations, however, the system has proven useful in detecting previously unrecognized adverse effects after immunization.

Vaccine history
The development of the acellular pertussis vaccine took many years. DTaP, as it is known, was first used beginning in 1991 for the fourth and fifth dose in the pertussis vaccination schedule for children aged 15 months through seven years. Scientists then analyzed the results from five million doses of DTaP given this way and found that the new vaccine was causing only one-third the complications of the whole-cell vaccine. So the new vaccine was licensed for use in infants in 1996 and the current study summarizes the results of its safety during its first two years of widespread use.

Additional post-approval studies undertaken by the vaccine manufacturers are underway. Continued monitoring and study should provide additional safety and effectiveness data.





Physician Referral Online

A free and confidential service
of Yale-New Haven Hospital.

Physician Referral Online
Using your own criteria, you can request information from a database of 900 area physicians who have registered to participate.

Request an appointment
We would be happy to assist you in scheduling an appointment with a member of the hospital's medical staff. Use the link above or call:

203-688-2000
or toll free
1-888-700-6543
to talk with a referral coordinator.


Eugene Shapiro, MD portrait.

Childhood vaccines continue to improve

Many new vaccines have been introduced in recent years, causing parents to generally be more aware of their safety and effectiveness. The new study released on the safety of the acellular pertussis vaccine should be greeted with enthusiasm. The trend is clear; the data presented in this study shows that the new vaccine is safer.

“In the past 20 years, several new vaccines have been either introduced or altered in some way.”

Over the years, it was thought that most of the serious adverse events that occurred the same time whole-cell pertussis vaccine was administered were not actually caused by the vaccine. There is no question less serious, but still significant, side effects such as fever were caused by the vaccine. The decrease in side effects reported in the acellular pertussis study could be due to reporting bias. That is, doctors may be less likely to attribute the serious events to the vaccine if they know child received the acellular vaccine. Still, the results are encouraging.

Continuing evolution of vaccines
In the past 20 years, several new vaccines have been either introduced or altered in some way. These developments mark the continuing quest of doctors and scientists to provide the best possible protection against disease at the lowest possible risk. Indeed, the success of immunizations has caused some parents to become complacent about vaccinating their children. After all, when was the last time a child you knew had measles? However, in areas where vaccinations rates are low, it is possible to see flare ups of these diseases, which years ago caused thousands of deaths and disabilities.

“The success of immunizations has caused some parents to become complacent about vaccinating their children.”

How vaccines work
Vaccines are made from either viral or bacterial sources. Viral vaccines are produced from either live (attenuated) or inactive (killed) viruses.

  • The measles, mumps and rubella (MMR) shot is an example of a live viral vaccine.
  • The vaccine for diphtheria, on the other hand, is made from an inactivated form of the toxin produced by the diphtheria bacteria.
  • The whole-cell version of the pertussis vaccine was made from the whole cell of the pertussis bacteria. The newer version uses only purified proteins taken from the bacteria.

Vaccines work this way. By placing a tiny amount of the virus or bacterial agent into the child, the child’s immune system is activated and produces antibodies to this specific substance. These antibodies stay with the child over the years and thus fight off the infectious agent if the child is later exposed. Immunizations are given early in life to protect children during their most vulnerable time.

“Immunizations are given early in life to protect children during their most vulnerable time [but]….it is never too late to get started.”

With many vaccines, several doses are required. The first three of the four-dose DTaP are given at two, four and six months of age. The vaccine for measles, mumps and rubella (MMR) is first given at 12 months and then usually again at age four or five but certainly by age 11. Children who did not begin their immunizations at two months of age or who have had only some of their shots can still be fully immunized. It is never too late to get started.

New vaccines introduced
Haemophilus influenzae type b (Hib) has been a serious disease in children, frequently resulting in complications, including meningitis. But then in 1985, the first version of a vaccine was introduced, with a conjugate version added three years later. Before the vaccine, we used to see 200 cases of invasive Hib disease in Connecticut alone each year. Now you can count the number on one hand.

In 1995, the chicken pox or varicella vaccine was approved and added to the vaccination schedule. Initially there were concerns about how long a child would be protected, but the effectiveness seems to be holding up very well.

Hepatitis B vaccine was first created in the early 1980s and targeted at adults at high risk of this blood-borne disease, such as health care workers, people with multiple sex partners or IV drug users. When that campaign was deemed ineffective, it was determined in 1992 that all infants would receive the vaccine and thereby receive life-long protection.

The four-dose conjugate pneumoccocal vaccine is the newest vaccine to be introduced this year. Pneumococcal disease is responsible for about 200 deaths each year among children under five years old. Children under age two or children age two to five at high risk of this disease should be vaccinated. Talk to your doctor or health care provider if you believe your youngster should receive this vaccination.

Flu shots for children?
Flu shots are not routinely recommended for children because they are not at high risk for complications of flu. However, there are some benefits. Flu shots can reduce cases of flu in children, particularly in the day care setting and have been shown to reduce the number of ear infections. In addition, children immunized against the flu provide one less way for the virus to spread. A flu shot has to be repeated each year. However, with the shortage of vaccine this season and the cost involved, it is unlikely that children will be receiving flu shots in large numbers.

Combination vaccines
Several drug companies are investigating whether it will be possible to develop new combinations of vaccines that are given as one shot, rather than multiple injections. Before this can occur, the safety and effectiveness of each combination needs to be confirmed.


Eugene Shapiro, MD, is a specialist in infectious diseases in children at Yale-New Haven Children’s Hospital and is professor of pediatrics at the Yale University School of Medicine.


HealthLink Sign Up.

Other related links.


Copyright 1999-2008.
Top of Page. Y-NHH. YNHHS. Site Editor.
Home page
Staff directory
Directions and parking
Online resources
Yale New Haven Health System
  Need a doctor?
Search
Comments
Top of page
Yale-New Haven Medical Center